Pharmaceutical giant AstraZeneca PLC said Thursday it has reached an agreement with Aspen Pharmacare Holdings Ltd. giving the Johannesburg-listed company rights to its anesthetics portfolio outside the U.S.
Under the deal, Aspen Global Incorporated, a unit of Aspen Pharmacare, will buy commercialization rights outside the U.S. to the portfolio for an upfront payment of $520 million.
Aspen will also pay AstraZeneca up to $250 million in a product sales-related payment, as well as double-digit percentage trademark royalties on product sales.
AstraZeneca said it will manufacture and supply the products on a cost plus basis to Aspen for an initial period of 10 years. Upon completion, Aspen will assume responsibility for all activities relating to the sale of the portfolio in all relevant markets, AstraZeneca added.
The deal isn’t expected to impact AstraZeneca’s financial guidance this year, the company said.
By Ian Walker
Source: MarketWatch
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.
